<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0307222298
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Staquis
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Crisaborole
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Ointment
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        340.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D11AH
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>STAQUIS is a prescription medicine used on the skin (topical) to treat mild to moderate eczema (atopic dermatitis) in adults and children 3 months of age and older.</p><p>&nbsp;</p><p>It is not known if STAQUIS is safe and effective in children under 3 months of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use STAQUIS: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Crisaborole or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist or nurse before taking Staquis about all f your medical conditions, including if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant.&nbsp; It is not known if STAQUIS will harm your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed.&nbsp; It is not known if STAQUIS passes into your breast milk.</p><p>&nbsp;</p><p>Do not use STAQUIS in your eyes, mouth, or vagina.</p><p><strong>&nbsp;</strong></p><p><strong>Children</strong></p><p>The safety and effectiveness of STAQUIS in pediatric patients below the age of 3 months have not been established</p><p>&nbsp;</p><p>Geriatric</p><p>Clinical studies of STAQUIS did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.</p><p>&nbsp;</p><p><strong>Other medicines and Staquis</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken&nbsp; or might take use any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and, breast-feeding and fertility</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Staquis effect on your ability to drive and use machines has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use STAQUIS exactly as your healthcare provider tells you to use it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply a thin layer of STAQUIS to the affected areas 2 times each day or as directed by your healthcare provider.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands after applying STAQUIS, unless hands are being treated. If someone else applies STAQUIS for you, they should wash their hands after applying STAQUIS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Allergic reactions:</strong> STAQUIS may cause allergic reactions at or near the application site or at a distant site which may be serious.&nbsp; Stop using STAQUIS and get medical help right away if you have any symptoms of an allergic reaction including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing or throat tightness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling faint</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, eyelids, lips, mouth, tongue or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness</p><p>&nbsp;</p><p>The most common side effect of STAQUIS is application site pain, such as burning or stinging.</p><p>This is not the only possible side effect of STAQUIS</p><p>&nbsp;</p><p><strong>Reporting side effects: </strong></p><p>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to National Pharmacovigilance &amp; Drug Safety Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30 &deg;C.</p><p>&nbsp;</p><p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Keep tube tightly closed.</p><p>&nbsp;</p><p>Do not use this Staquis after the expiry date which is stated on the tube and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice visible signs of deterioration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is crisaborole.</p><p>One g of ointment contains 20 mg of crisaborole.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are white petrolatum USP, propylene glycol USP, mono- and di-glycerides NF, paraffin NF, butylated hydroxytoluene NF, and edetate calcium disodium USP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                STAQUIS is a white to off-white ointment containing 2% crisaborole and is supplied in 60 g laminate tubes.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Inc., USA</p><p>&nbsp;</p><p><strong>Manufactured by:</strong></p><p><strong>&nbsp;</strong></p><p>Pharmacia &amp; Upjohn Company</p><p>Kalamazoo, USA</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ستاكيوس هو دواء يؤخذ بوصفة طبية يستخدم على الجلد (استخدام موضعي) لعلاج الإكزيما الخفيفة إلى المتوسطة (التهاب الجلد التأتبي) في البالغين والأطفال الذين يبلغون من العمر 3 أشهر فأكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان ستاكيوس آمنًا وفعالًا مع الأطفال الأقل عمرًا من 3 أشهر أم لا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال ستاكيوس </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه كريزابرول أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ستاكيوس </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة قبل تناول ستاكيوس بكل حالاتك الطبية، بما في ذلك إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملًا أو تخططين للحمل.&nbsp; من غير المعروف إذا ما كان ستاكيوس سيضر بجنينكِ أم لا.</p><p dir="RTL">&bull;&nbsp;&nbsp; كنتِ تُرضعين رضاعة طبيعية أو تخططين لذلك.&nbsp; من غير المعروف إذا ما كان ستاكيوس يمر إلى لبن الثدي لديكِ أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمنع وضع ستاكيوس على العينين أو الفم أو المهبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لم يتم إثبات سلامة وفعالية ستاكيوس مع المرضى من الأطفال الذين يقل عمرهم عن ٣ أشهر</p><p dir="RTL">&nbsp;</p><p>المسنون</p><p dir="RTL">لم تتضمن الدراسات الإكلينيكية على ستاكيوس عددًا كافيًا من الأشخاص الخاضعين للدراسة البالغين من العمر ٦٥ عامًا فأكثر لتحديد ما إذا كانوا سيستجيبون بشكل مختلف عن الأشخاص الخاضعين للدراسة الأصغر عمرًا أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ستاكيوس في القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لم يثبت تأثير ستاكيوس في قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم ستاكيوس تمامًا كما يخبرك مُقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع طبقة رقيقة من ستاكيوس على المناطق المصابة مرتين كل يوم أو كما يوجهك مقدم الرعاية الصحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك بعد وضع ستاكيوس، إلا إذا كان يستخدم لعلاج اليدين. إذا قام شخص آخر بوضع ستاكويس لك، ينبغي له غسل يديه بعد وضعه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong><strong>:</strong> قد يسبب ستاكيوس تفاعلات حساسية في موضع الاستخدام أو بجانبه أو في موضع بعيد عنه، وقد تكون هذه التفاعلات خطيرة. توقف عن استخدام ستاكيوس واحصل على مساعدة طبية فورًا إذا ظهرت عليك أي من أعراض تفاعل الحساسية، بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس أو تضيق الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وجهك أو جفنيك أو شفتيك أو فمك أو لسانك أو حلقك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p><p dir="RTL">&nbsp;</p><p dir="RTL">العرض الجانبي الأكثر شيوعًا لستاكيوس هو الألم في موضع الاستخدام، مثل الشعور بحرقة أو وخز.</p><p dir="RTL">هذا ليس العرض الجانبي الوحيد المحتمل لستاكيوس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية: </strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية لم يتم ذكرها في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً إلى المركز الوطني للتيقظ والسلامة الدوائية. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائيمركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ الأنبوب وهو محكم الإغلاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم ستاكيوس بعد تاريخ انتهاء الصلاحية المدون على الأنبوب والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت وجود علامات تلف ظاهرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي كريزابرول.</p><p dir="RTL">يحتوي جم واحد من المرهم على ٢٠ ملجم من كريزابرول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي فازلين أبيض وفقًا لدستور الأدوية الأمريكي (USP)، وبروبيلين جليكول وفقًا لدستور الأدوية الأمريكي، وجليسيريدات أحادية وثنائية وفقًا لكتيب الوصفات الوطني (NF)، وبارافين وفقًا لكتيب الوصفات الوطني، وهيدروكسي تولوين البوتيلي وفقًا لكتيب الوصفات الوطني، وإيديتات كالسيوم ثنائي الصوديوم وفقًا لدستور الأدوية الأمريكي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستاكيوس هو مرهم لونه أبيض إلى أبيض مائل إلى الصفرة يحتوي على كريزابرول بنسبة 2 % ويتم توفيره في أنابيب من طبقات رقيقة سعة 60 جم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Inc., USA، الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL">Pharmacia &amp; Upjohn Company</p><p dir="RTL">Kalamazoo, USA، الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                STAQUIS 2% Ointment
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
STAQUIS contains 2% crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use.  The active ingredient, crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor. 

Crisaborole is described chemically as 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole.  The empirical formula is C14H10BNO3 and the molecular weight is 251.1 g/mol.

The structural formula is represented below:
 

Crisaborole drug substance is freely soluble in common organic solvents such as isopropyl alcohol and propylene glycol, and insoluble in water.

Each gram of STAQUIS contains 20 mg of crisaborole in an ointment containing white petrolatum, propylene glycol, mono- and di-glycerides, paraffin, butylated hydroxytoluene, and edetate calcium disodium.
One gram of ointment contains 20 mg of crisaborole.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ointment: 20 mg of crisaborole per gram (2%) of white to off-white ointment.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>STAQUIS is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Apply a thin layer of STAQUIS twice daily to affected areas. Once clinical effect is achieved, consider reducing application to once daily <em>[see section 5.1].</em></p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p><u>Pediatric Use</u></p><p>The safety and effectiveness of STAQUIS have been established in pediatric patients ages 3 months and older for topical treatment of mild to moderate atopic dermatitis. Use of STAQUIS administered twice daily in this age group is supported by data from two 28-day adequate, vehicle controlled safety and efficacy trials (1,313 pediatric subjects ages 2 years to 17 years of whom 874 received STAQUIS), a 28 -day open -label, safety and pharmacokinetics (PK) trial (137 subjects ages 3 months to less than 2 years who received STAQUIS), and another trial with an open label period of up to 8 weeks (327 pediatric subjects ages 5 months to less than 18 years who received STAQUIS) [<em>see </em>section 5.2 and section 5.1].</p><p>&nbsp;</p><p>The safety and effectiveness of STAQUIS in pediatric patients below the age of 3 months have not been established.</p><p>&nbsp;</p><p><u>Geriatric Use</u></p><p>Clinical studies of STAQUIS did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>STAQUIS is for topical use only and not for ophthalmic, oral, or intravaginal use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                STAQUIS is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. [see section 4.4]
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity Reactions</strong></p><p>Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with STAQUIS. Hypersensitivity should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site.&nbsp; If signs and symptoms of hypersensitivity occur, discontinue STAQUIS immediately and initiate appropriate therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patient Counseling Information</p><p>Advise the patient or caregivers to read the FDA-approved patient labeling (Patient Information).</p><p>&nbsp;</p><p><u>Hypersensitivity Reactions</u><u>:</u></p><p>Advise patients to discontinue STAQUIS and seek medical attention immediately if signs or symptoms of hypersensitivity occur.</p><p><u>Administration</u><u> Instructions: </u></p><p>Advise patients or caregivers that STAQUIS is for external use only and is not for ophthalmic, oral, or intravaginal use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drug Interaction Studies</strong></p><p>In vitro<em> </em>studies using human liver microsomes indicated that under the conditions of clinical use, crisaborole and metabolite 1 are not expected to inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4.</p><p>In vitro human liver microsomes studies for metabolite 2 showed that it did not inhibit activities of CYP2C19, 2D6, and 3A4; was a weak inhibitor of CYP1A2 and 2B6; and a moderate inhibitor of CYP2C8 and 2C9.&nbsp; The most sensitive enzyme, CYP2C9, was further investigated in a clinical trial using warfarin as a CYP2C9 substrate.&nbsp; The results of this study showed no drug interaction potential.&nbsp;</p><p>In vitro<em> </em>studies in human hepatocytes showed that under the conditions of clinical use, crisaborole and metabolites 1 and 2 are not expected to induce CYP enzymes.&nbsp;</p><p>In vitro studies showed that crisaborole and metabolite 1 did not inhibit the activities of uridine diphosphate (UDP)‑glucuronosyltransferase (UGT) 1A1, 1A4, 1A6, 1A9, 2B7, and 2B15.&nbsp; Metabolite 2 did not inhibit UGT1A4, 1A6, 2B7, and 2B15. Metabolite 2 showed weak inhibition of UGT1A1, however, no clinically significant drug interactions are expected between crisaborole (and its metabolites) and UGT1A1 substrates at therapeutic concentrations.&nbsp; Metabolite 2 showed moderate inhibition of UGT1A9 and may result in a moderate increase of the concentrations of sensitive UGT1A9 substrates.</p><p>&nbsp;</p><p>In vitro studies indicate that under the condition of clinical use, crisaborole and metabolites 1 and 2 are not expected to cause clinically significant interactions with substrates of P-glycoprotein and organic anionic or cationic transporters.&nbsp; Crisaborole and metabolite 1 are not expected to inhibit breast cancer resistance protein (BCRP); metabolite 2 is expected to inhibit BCRP at therapeutic concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><strong>Risk Summary</strong></p><p>Available data from case reports with STAQUIS use in pregnant women are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD) (<em>see Data</em>).</p><p>&nbsp;</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects in the U.S. general population is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p><p>&nbsp;</p><p><strong>Data</strong></p><p><em>Animal Data</em></p><p>Rat and rabbit embryo-fetal development was assessed after oral administration of crisaborole. Crisaborole did not cause adverse effects to the fetus at oral doses up to 300&nbsp;mg/kg/day in pregnant rats during the period of organogenesis (3 times the MRHD on an area under the curve (AUC) comparison basis). No crisaborole-related fetal malformations were noted after oral treatment with crisaborole in pregnant rats at doses up to 600 mg/kg/day (13 times the MRHD on an AUC comparison basis) during the period of organogenesis.&nbsp; Maternal toxicity was produced at this high dose of 600 mg/kg/day in pregnant rats and was associated with decreased fetal body weight and delayed skeletal ossification. Crisaborole did not cause adverse effects to the fetus at oral doses up to the highest dose tested of 100 mg/kg/day in pregnant rabbits during the period of organogenesis (2 times the MRHD on an AUC comparison basis).</p><p>&nbsp;</p><p>In a prenatal/postnatal development study, pregnant rats were treated with crisaborole at doses of 150, 300, or 600 mg/kg/day by oral gavage during gestation and lactation (from gestation day 7 through day 20 of lactation).&nbsp; Crisaborole did not have any adverse effects on fetal development at doses up to 300 mg/kg/day (3times the MRHD on an AUC comparison basis).&nbsp; Maternal toxicity was produced at the high dose of 600 mg/kg/day in pregnant rats and was associated with stillbirths, pup mortality, and reduced pup weights.</p><p>&nbsp;</p><p><u>Lactation</u></p><p><strong>Risk Summary</strong></p><p>There is no information available on the presence of STAQUIS in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of STAQUIS to women who are breastfeeding.&nbsp; STAQUIS is systemically absorbed.&nbsp; The lack of clinical data during lactation precludes a clear determination of the risk of STAQUIS to a breastfed infant.&nbsp; Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for STAQUIS and any potential adverse effects on the breastfed infant from STAQUIS or from the underlying maternal condition.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>No effects on fertility were observed in male or female rats that were administered oral doses up to 600 mg/kg/day crisaborole (13 times the MRHD on an AUC comparison basis) prior to and during early pregnancy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>In two double-blind, vehicle-controlled clinical trials (Trial 1 and Trial 2), 1012 subjects 2 to 79 years of age with mild to moderate atopic dermatitis were treated with STAQUIS twice daily for 4 weeks.&nbsp; The adverse reaction reported by &ge;1% of STAQUIS-treated subjects is listed in Table 1.</p><p>&nbsp;</p><p>Table 1: Adverse Reaction Occurring in &ge;1% of Subjects in Atopic Dermatitis Trials through Week 4</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>STAQUIS</strong></p><p><strong>Twice Daily</strong></p><p><strong>N=1012</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Vehicle </strong></p><p><strong>Twice Daily</strong></p><p><strong>N=499</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Application site pain<sup>a</sup></p></td><td style="vertical-align:top"><p>45 (4)</p></td><td style="vertical-align:top"><p>6 (1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a&nbsp;&nbsp;&nbsp; </sup>Refers to skin sensations such as burning or stinging.</p></td></tr></tbody></table><p>&nbsp;</p><p>Less common (&lt;1%) adverse reactions in subjects treated with STAQUIS included contact urticaria <em>[see section 4.4].</em></p><p>&nbsp;</p><p>In one double-blind, vehicle-controlled trial including an initial open label period (Trial 3), 497 subjects 3 months of age and older with mild to moderate atopic dermatitis received STAQUIS twice daily for up to 8 weeks. This was followed by a double-blind period, during which 135 subjects out of 270 randomized subjects received STAQUIS and 135 subjects received vehicle once daily for 52 weeks or until they developed a flare. The adverse reactions observed in the open-label period were similar to the known safety profile of twice daily treatment with STAQUIS. The adverse reactions observed with once daily treatment were similar to vehicle [<em>see</em> section 5.1]. &nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Adverse reactions are ranked under headings of frequency, with the most frequent first, using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 2: Adverse reactions</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>&nbsp;&ge; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>&lt; 1/10,000</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>not known</strong></p><p><strong>(cannot be</strong></p><p><strong>estimated</strong></p><p><strong>from the available</strong></p><p><strong>data)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Application site reactions (e.g., application site pain<sup>*</sup>, application site pruritus)<sup> </sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>*</sup> Refers to skin sensations such as burning or stinging</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during postapproval use of STAQUIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</p><p>&nbsp;</p><p><em>Skin and Subcutaneous: </em>allergic contact dermatitis</p><p>&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance and Drug Safety Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of Action</u></p><p>Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.</p><p><u>&nbsp;</u></p><p><em>Cardiac Electrophysiology</em></p><p>At therapeutic doses, STAQUIS ointment is not expected to prolong QTc to any clinically relevant extent.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Two multicenter, randomized, double-blind, parallel-group, vehicle-controlled trials (Trials 1 and 2) treated a total of 1522 subjects 2 to 79 years of age (86.3% of subjects were 2 to 17 years of age) with a 5% to 95% treatable BSA.&nbsp; At baseline, 38.5% of the subjects had an Investigator&rsquo;s Static Global Assessment [ISGA] of mild (2), and 61.5% had an ISGA of moderate (3), in the overall assessment of atopic dermatitis (erythema, induration/papulation, and oozing/crusting) on a severity scale of 0 to 4.&nbsp;</p><p>&nbsp;</p><p>In both trials, subjects were randomized 2:1 to receive STAQUIS or vehicle applied twice daily for 28 days.&nbsp; The primary efficacy endpoint was the proportion of subjects at Day 29 who achieved success, defined as an ISGA grade of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline, comparing STAQUIS-treated subjects to vehicle-treated subjects.</p><p>&nbsp;</p><p>Efficacy results from the two trials are summarized in Table 3.</p><p>&nbsp;</p><p><strong>Table&nbsp;3: Primary Efficacy Outcomes in Subjects with Mild to Moderate Atopic Dermatitis at Day 29<sup> </sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>Trial 1</p></td><td colspan="2" style="vertical-align:bottom"><p>Trial 2</p></td></tr><tr><td style="vertical-align:bottom"><p>STAQUIS<br />Twice Daily</p><p>(N=503)</p></td><td style="vertical-align:bottom"><p>Vehicle<br />Twice Daily (N=256)</p></td><td style="vertical-align:bottom"><p>STAQUIS<br />Twice Daily</p><p>(N=513)</p></td><td style="vertical-align:bottom"><p>Vehicle<br />Twice Daily (N=250)</p></td></tr><tr><td style="vertical-align:top"><p>Success in ISGA<sup>a</sup></p></td><td style="vertical-align:bottom"><p>32.8%</p></td><td style="vertical-align:bottom"><p>25.4%</p></td><td style="vertical-align:bottom"><p>31.4%</p></td><td style="vertical-align:bottom"><p>18.0%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp; Defined as an ISGA of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline.</p></td></tr></tbody></table><p>&nbsp;</p><p>The success rates over time are presented in Figure 1.</p><p>&nbsp;</p><p><strong>Figure 1: Success in ISGA<sup>a</sup> Over Time in Subjects with Mild to Moderate Atopic Dermatitis</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:647px"><tbody><tr><td style="vertical-align:top"><p><strong>Trial 1</strong></p></td><td style="vertical-align:top"><p><strong>Trial 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_8" o:spid="_x0000_s1028" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:326.85pt;
 margin-top:267.45pt;width:109.5pt;height:18.45pt;z-index:251663360;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="146" height="25" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /><!--[if gte vml 1]><v:shape id="Picture_x0020_1"
 o:spid="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:129.85pt;margin-top:271.05pt;width:105.6pt;
 height:18.5pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="141" height="25" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_2" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:194.25pt;
 height:132.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png"
  o:title=""/>
</v:shape><![endif]--><img width="259" height="177" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.jpg" /><!--[if gte vml 1]><v:shape id="Picture_x0020_6"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:201pt;height:135pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
</v:shape><![endif]--><img width="268" height="180" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.jpg" /></p><p><sup>&nbsp;</sup></p><p><sup>a</sup>&nbsp; Success is defined as an ISGA of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline.</p><p><strong>&nbsp;</strong></p><p>One randomized, double-blind, vehicle-controlled trial (Trial 3) assessed the efficacy and safety of &nbsp;STAQUIS once daily over 52 weeks in pediatric (3 months to less than 18 years of age) and adult subjects with mild to moderate atopic dermatitis, who achieved success on STAQUIS twice daily during open-label treatment of up to 8 weeks.</p><p>&nbsp;</p><p>A total of 497 subjects 3 months of age and older with a 2% to 90% treatable BSA, entered into an open‑label period to receive STAQUIS twice daily for up to 8 weeks. At baseline, 327 (66%) of subjects were 3 months to less than 18 years of age, 66% of the subjects had an ISGA of moderate (3), and 34% had an ISGA of mild (2), in the overall assessment of atopic dermatitis (erythema, induration/papulation, and oozing/crusting) on a severity scale of 0 to 4.</p><p>&nbsp;</p><p>Of the 497, a total of 254 subjects 3 months of age and older, who achieved both ISGA success (score of clear [0] or almost clear [1] with a &ge;2 grade improvement from baseline) and EASI50 response (at least 50% improvement from baseline in EASI scores) were randomized 1:1 into a double-blind period to receive STAQUIS once daily or vehicle for 52 weeks or until they developed a flare. At the beginning of the double‑blind period, 59% of the subjects had an ISGA of almost clear (1) and 41% had an ISGA of clear (0).</p><p>&nbsp;</p><p>Figure 2 presents the percentage of subjects maintaining an ISGA of clear or almost clear through Week 52.</p><p><em>&nbsp;</em></p><p><strong>Figure 2: Percentage of Subjects Maintaining ISGA of Clear or Almost Clear Through Week 52</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_10" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 margin-left:117.5pt;margin-top:103.85pt;width:134.8pt;height:21.55pt;
 z-index:251665408;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png"
  o:title=""/>
 <w:wrap anchorx="margin" anchory="page"/>
</v:shape><![endif]--><img width="180" height="29" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_9" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:260.25pt;
 height:214.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.emz"
  o:title=""/>
</v:shape><![endif]--><img width="347" height="286" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.png" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>The PK of STAQUIS were investigated in 33 pediatric subjects 2 to 17 years of age with mild to moderate atopic dermatitis and a mean &plusmn; SD body surface area (BSA) involvement of 49 &plusmn; 20% (range 27% to 92%).&nbsp; In this study, subjects applied approximately 3 mg/cm<sup>2</sup> of STAQUIS ointment (dose range was approximately 6 g to 30 g per application) twice daily for 8 days.</p><p>Plasma concentrations were quantifiable in all the subjects.&nbsp; The mean &plusmn; SD maximum plasma concentration (C<sub>max</sub>) and area under the concentration time curve from 0 to 12 hours post dose (AUC<sub>0-12</sub>)<sub> </sub>for crisaborole on Day 8 were 127 &plusmn; 196 ng/mL and 949 &plusmn; 1240 ngh/mL, respectively.&nbsp; Systemic concentrations of crisaborole were at steady state by Day 8.&nbsp; Based on the ratios of AUC<sub>0-12 </sub>between Day 8 and Day 1, the mean accumulation factor for crisaborole was 1.9.</p><p>The PK of STAQUIS were investigated in 13 subjects 4 months to less than 24 months of age.&nbsp; The mean &plusmn; SD C<sub>max</sub> and AUC<sub>0-12 </sub>for crisaborole were 188 &plusmn; 100&nbsp;ng/mL and 1164 &plusmn; 550&nbsp;ng∙h/mL, respectively.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>Based on an in vitro study, crisaborole is 97% bound to human plasma proteins.</p><p><strong>Elimination</strong></p><p><strong><em>Metabolism</em></strong></p><p>Crisaborole is substantially metabolized into inactive metabolites.&nbsp; The major metabolite 5-(4-cyanophenoxy)-2-hydroxyl benzylalcohol (metabolite 1), is formed via hydrolysis; this metabolite is further metabolized into downstream metabolites, among which 5-(4-cyanophenoxy)-2-hydroxyl benzoic acid (metabolite 2), formed via oxidation, is also a major metabolite.</p><p>PK of metabolites 1 and 2 were assessed in the PK study described above and the systemic concentrations were at or near steady state by Day 8.&nbsp; Based on the ratios of AUC<sub>0-12 </sub>between Day 8 and Day 1, the mean accumulation factors for metabolites 1 and 2 were 1.7 and 6.3, respectively.</p><p><strong><em>Excretion</em></strong></p><p>Renal excretion of metabolites is the major route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 30, 100, or 300 mg/kg/day crisaborole were administered to rats once daily.&nbsp; A crisaborole-related increased incidence of benign granular cell tumors in the uterus with cervix and vagina (combined) was noted in 300 mg/kg/day crisaborole treated female rats (2 times the MRHD on an AUC comparison basis).&nbsp; The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>In a dermal carcinogenicity study in CD-1 mice, topical doses of 2%, 5% or 7% crisaborole ointment were administered once daily.&nbsp; No crisaborole-related neoplastic findings were noted at topical doses up to 7% crisaborole ointment (1 times the MRHD on an AUC comparison basis).</p><p>&nbsp;</p><p>Crisaborole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each gram contains: 20 mg of crisaborole in an ointment containing white petrolatum USP, propylene glycol USP, mono- and</p><p>di-glycerides NF, paraffin NF, butylated hydroxytoluene NF, and edetate calcium disodium USP.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

Do not use Staquis after the expiry date which is stated on the tube and carton after EXP:. The expiry date refers to the last day of that month.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>STAQUIS is a white to off-white ointment containing 2% crisaborole and is supplied in 60 g laminate tubes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Keep tube tightly closed.</p><p><em>&nbsp;</em></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Inc., USA

MANUFACUTRED BY

Pharmacia & Upjohn Company
Kalamazoo, USA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>